What are the major opportunities in the Duchenne Muscular Dystrophy market? What are the strategies for the Duchenne Muscular Dystrophy market?

For detailed insights on the major opportunities and strategies in the Duchenne Muscular Dystrophy market, Read More

How does the Duchenne Muscular Dystrophy market relate to the overall economy and other similar markets?

For detailed insights on Duchenne Muscular Dystrophy's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Duchenne Muscular Dystrophy market growth? SWOT analysis of the Duchenne Muscular Dystrophy market.

For detailed insights on the key dynamics influencing the Duchenne Muscular Dystrophy market growth and SWOT analysis of the Duchenne Muscular Dystrophy industry, Read More

Global Duchenne Muscular Dystrophy Market Report 2025

Item added to cart!

Published : December 2025

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Duchenne Muscular Dystrophy Global Market Report 2025

Name: Duchenne Muscular Dystrophy Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Therapy (Mutation Suppression, Exon Skipping Approach), By Therapeutic Class (Molecular Based Therapies, Steroid Therapy), By Route of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Other End-Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Duchenne Muscular Dystrophy Market Overview

• Duchenne Muscular Dystrophy market size has reached to $1.16 billion in 2024

• Expected to grow to $1.72 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%

• Growth Driver: Rising Prevalence Of Chronic Diseases Fuels Growth In The Duchenne Muscular Dystrophy Market

• Market Trend: Technological Advancements In Clinical Trial Simulator Boost Duchenne Muscular Dystrophy Market

• North America was the largest region in 2024.

What Is Covered Under Duchenne Muscular Dystrophy Market?

Duchenne muscular dystrophy is a genetic disease that causes gradual muscle loss, affecting the skeletal, cardiac, and lung muscles. It is caused by a mutation in the gene responsible for producing dystrophin, a protein that is crucial for the healthy operation of muscles.

The main types of therapies included in duchenne muscular dystrophy are mutation suppression and exon skipping approach. Exon skipping is the most prevalent type of alternative splicing, in which introns and intervals on a pre-mRNA molecule that ordinarily function as exons of a gene are removed together when a final mRNA is formed. therapeutic classes included are molecular-based therapies and steroid therapy and the route of administration are oral, parenteral, and others. These are distributed through hospital pharmacies, online pharmacies, and retail pharmacies for use in end-users such as hospitals, homecare, specialty clinics, and others.

Duchenne Muscular Dystrophy Market Size and growth rate 2025 to 2029: Graph

What Is The Duchenne Muscular Dystrophy Market Size 2025 And Growth Rate?

What Is The Duchenne Muscular Dystrophy Market Growth Forecast?

The duchenne muscular dystrophy market size is expected to see strong growth in the next few years. It will grow to $1.72 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to emerging gene therapies, precision medicine approaches, expanded access to therapies, long-term follow-up studies, regulatory advancements. Major trends in the forecast period include integration of digital health technologies, technological advancements in therapeutics, gene therapies and genetic medicines, regulatory support for orphan drugs, precision medicine approaches.

The forecast of 8.2% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. patients by increasing costs of genetic testing kits and mobility aids imported from the UK and the Netherlands, potentially reducing treatment accessibility and raising long-term care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Duchenne Muscular Dystrophy Market Segmented?

1) By Therapy: Mutation Suppression, Exon Skipping Approach

2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Mutation Suppression: Antisense Oligonucleotides (ASOs), Small Molecules, Gene Therapy

2) By Exon Skipping Approach: Exon-Skipping Therapies, Combination Therapies, Clinical Trials And Investigational Drugs

What Is Driving The Duchenne Muscular Dystrophy Market? Rising Prevalence Of Chronic Diseases Fuels Growth In The Duchenne Muscular Dystrophy Market

The increasing prevalence of chronic diseases is expected to propel the growth of the Duchenne muscular dystrophy market in the future. A chronic disease is a health issue or condition with long-lasting symptoms lasting for at least a year. The Duchenne muscular dystrophy contributes to the prevalence of chronic diseases by addressing the specific therapeutic needs of individuals with this genetic disorder, highlighting the broader significance of personalized medicine in managing and potentially mitigating the impact of chronic conditions. For instance, in January 2023, according to the National Library of Medicine, a US-based government agency, the number of people in the US aged 50 and older who have at least 1 chronic condition would increase to 142.66 million by 2050. Therefore, the increasing prevalence of chronic diseases is driving the growth of the Duchenne muscular dystrophy industry.

What Is Driving The Duchenne Muscular Dystrophy Market? Rising Demand For Personalized Medicine Drives Growth In The Duchenne Muscular Dystrophy Market

The growing demand for personalized medicine is expected to propel the Duchenne muscular dystrophy market's growth in the future. Personalized medicine tailors medical treatment to an individual's unique characteristics, such as genetic makeup or lifestyle, resulting in more effective and precise healthcare outcomes. Personalized medicine is used to manage Duchenne muscular dystrophy (DMD), by tailoring treatments based on individual factors advances therapeutic efficacy and improves patient outcomes. For instance, in February 2023, according to a report published by the Personalized Medicine Coalition, a US-based professional membership organization, the approval of 12 new personalized medicines in 2022, accounting for around 34% of all new therapies, reflected a significant rise compared to previous years. Therefore, the growing demand for personalized medicine is driving the Duchenne muscular dystrophy industry's growth.

Who Are The Major Players In The Global Duchenne Muscular Dystrophy Market?

Major companies operating in the duchenne muscular dystrophy market include Pfizer Inc., GlaxoSmithKline plc, PerkinElmer Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., WAVE Life Sciences Ltd., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc.

What Are The Key Trends Of The Global Duchenne Muscular Dystrophy Market? Technological Advancements In Clinical Trial Simulator Boost Duchenne Muscular Dystrophy Market

Major companies operating in the Duchenne muscular dystrophy market are developing technological advancements, such as clinical trial design, to enhance the efficiency and effectiveness of drug development processes, improve patient outcomes, and accelerate the approval of new therapies. Clinical trial design is the process of organizing and planning a clinical trial to evaluate a new treatment's safety and effectiveness, including defining goals, selecting participants, and outlining methods and analyses. For instance, in March 2024, Critical Path Institute (C-Path), a US-based non-profit organization, launched the DMD Clinical Trial Simulator (CTS). This innovative tool, developed by C-Path's Duchenne Regulatory Science Consortium, aims to optimize the design of efficacy studies for DMD therapies. Key features of the CTS include advanced modeling of functional test performance, the capability to simulate various scenarios, increased efficiency in trial design, and public accessibility via the C-Path website and the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). As such, IT serves as a valuable resource for researchers and pharmaceutical companies engaged in DMD research.

What Are The Key Trends Of The Global Duchenne Muscular Dystrophy Market? Pioneering Gene Therapy For Duchenne Muscular Dystrophy Marks A Revolutionary Milestone In Treatment Innovation

Major companies operating in the Duchenne muscular dystrophy market are focusing on product innovations, such as the first gene therapy to treat Duchenne Muscular Dystrophy. This therapy involves introducing functional copies of the dystrophin gene into affected individuals to address the genetic mutation responsible for the progressive muscle degeneration characteristic of the disease. For instance, in June 2023, Sarepta Therapeutics, a US-based biopharmaceutical company that develops RNA-based treatments for rare and infectious diseases, announced FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy. This groundbreaking one-time treatment utilizes advanced gene therapy technology to address the genetic cause of the disease. Its significance lies in revolutionizing DMD treatment, representing a breakthrough from traditional supportive care approaches, potentially enhancing patients' quality of life and life expectancy while showcasing the transformative potential of gene therapy in addressing rare diseases.

Need data on a specific region in this market?

Request Regional Data

Duchenne Muscular Dystrophy Market Merger And Acquisition: Solid Biosciences Expands Neuromuscular And Cardiac Programs Through Acquisition Of AavantiBio

In December 2022, Solid Biosciences, a US-based based life sciences company focused on developing on advancing a portfolio of neuromuscular and cardiac programs acquired AavantiBio for an undisclosed amount. With this acquisition, the combined company will focus on developing variety of neuromuscular and cardiac programs, including SGT-003, Solid's next-generation gene transfer candidate for the treatment of Duchenne. AavantiBio, Inc. is a US-based biotechnology company focused on developing gene therapies to transform the lives of patients with rare genetic diseases.

Regional Outlook For The Global Duchenne Muscular Dystrophy Market

North America was the largest region in the Duchenne muscular dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Duchenne Muscular Dystrophy Market?

The duchenne muscular dystrophy market includes revenues earned by entities by providing respiratory therapy, physical therapy and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Duchenne Muscular Dystrophy Industry?

The duchenne muscular dystrophy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the duchenne muscular dystrophy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Duchenne Muscular Dystrophy Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$1.25 billion
Revenue Forecast In 2034	$1.72 billion
Growth Rate	CAGR of 8.2% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Therapy: Mutation Suppression, Exon Skipping Approach 2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy 3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Mutation Suppression: Antisense Oligonucleotides (ASOs), Small Molecules, Gene Therapy 2) By Exon Skipping Approach: Exon-Skipping Therapies, Combination Therapies, Clinical Trials And Investigational Drugs
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., GlaxoSmithKline plc, PerkinElmer Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., WAVE Life Sciences Ltd., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Duchenne Muscular Dystrophy Market Characteristics

3. Duchenne Muscular Dystrophy Market Trends And Strategies

4. Duchenne Muscular Dystrophy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Duchenne Muscular Dystrophy Growth Analysis And Strategic Analysis Framework

5.1. Global Duchenne Muscular Dystrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Duchenne Muscular Dystrophy Market Growth Rate Analysis

5.4. Global Duchenne Muscular Dystrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Duchenne Muscular Dystrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Duchenne Muscular Dystrophy Total Addressable Market (TAM)

6. Duchenne Muscular Dystrophy Market Segmentation

6.1. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Mutation Suppression

Exon Skipping Approach

6.2. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Molecular Based Therapies

Steroid Therapy

6.3. Global Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Parenteral

Other Routes Of Administration

6.4. Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

6.5. Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Homecare

Specialty Clinics

Other End-Users

6.6. Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Mutation Suppression, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Antisense Oligonucleotides (ASOs)

Small Molecules

Gene Therapy

6.7. Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Exon Skipping Approach, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Exon-Skipping Therapies

Combination Therapies

Clinical Trials And Investigational Drugs

7. Duchenne Muscular Dystrophy Market Regional And Country Analysis

7.1. Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Duchenne Muscular Dystrophy Market

8.1. Asia-Pacific Duchenne Muscular Dystrophy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Duchenne Muscular Dystrophy Market

9.1. China Duchenne Muscular Dystrophy Market Overview

9.2. China Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Duchenne Muscular Dystrophy Market

10.1. India Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Duchenne Muscular Dystrophy Market

11.1. Japan Duchenne Muscular Dystrophy Market Overview

11.2. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Duchenne Muscular Dystrophy Market

12.1. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Duchenne Muscular Dystrophy Market

13.1. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Duchenne Muscular Dystrophy Market

14.1. South Korea Duchenne Muscular Dystrophy Market Overview

14.2. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Duchenne Muscular Dystrophy Market

15.1. Western Europe Duchenne Muscular Dystrophy Market Overview

15.2. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Duchenne Muscular Dystrophy Market

16.1. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Duchenne Muscular Dystrophy Market

17.1. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Duchenne Muscular Dystrophy Market

18.1. France Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Duchenne Muscular Dystrophy Market

19.1. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Duchenne Muscular Dystrophy Market

20.1. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Duchenne Muscular Dystrophy Market

21.1. Eastern Europe Duchenne Muscular Dystrophy Market Overview

21.2. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Duchenne Muscular Dystrophy Market

22.1. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Duchenne Muscular Dystrophy Market

23.1. North America Duchenne Muscular Dystrophy Market Overview

23.2. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Duchenne Muscular Dystrophy Market

24.1. USA Duchenne Muscular Dystrophy Market Overview

24.2. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Duchenne Muscular Dystrophy Market

25.1. Canada Duchenne Muscular Dystrophy Market Overview

25.2. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Duchenne Muscular Dystrophy Market

26.1. South America Duchenne Muscular Dystrophy Market Overview

26.2. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Duchenne Muscular Dystrophy Market

27.1. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Duchenne Muscular Dystrophy Market

28.1. Middle East Duchenne Muscular Dystrophy Market Overview

28.2. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Duchenne Muscular Dystrophy Market

29.1. Africa Duchenne Muscular Dystrophy Market Overview

29.2. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Duchenne Muscular Dystrophy Market Competitive Landscape And Company Profiles

30.1. Duchenne Muscular Dystrophy Market Competitive Landscape

30.2. Duchenne Muscular Dystrophy Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

30.2.3. PerkinElmer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Duchenne Muscular Dystrophy Market Other Major And Innovative Companies

31.1. PTC Therapeutics Inc.

31.2. Asklepios BioPharmaceutical Inc.

31.3. Catabasis Pharmaceuticals Inc.

31.4. Wave Life Sciences Ltd.

31.5. Bristol Myers Squibb Company

31.6. BridgeBio Pharma Inc.

31.7. Rocket Pharmaceuticals Inc.

31.8. Italfarmaco SpA

31.9. Solid Biosciences Inc.

31.10. Avidity Biosciences Inc.

31.11. Fulcrum Therapeutics Inc.

31.12. Akashi Therapeutics Inc.

31.13. WAVE Life Sciences Ltd.

31.14. Capricor Therapeutics Inc.

31.15. Santhera Pharmaceuticals Holding

32. Global Duchenne Muscular Dystrophy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Market

34. Recent Developments In The Duchenne Muscular Dystrophy Market

35. Duchenne Muscular Dystrophy Market High Potential Countries, Segments and Strategies

35.1 Duchenne Muscular Dystrophy Market In 2029 - Countries Offering Most New Opportunities

35.2 Duchenne Muscular Dystrophy Market In 2029 - Segments Offering Most New Opportunities

35.3 Duchenne Muscular Dystrophy Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Mutation Suppression, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Exon Skipping Approach, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Pfizer Inc. Financial Performance

Table 79: GlaxoSmithKline plc Financial Performance

Table 80: PerkinElmer Inc. Financial Performance

Table 81: BioMarin Pharmaceutical Inc. Financial Performance

Table 82: Sarepta Therapeutics Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Mutation Suppression, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Exon Skipping Approach, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Pfizer Inc. Financial Performance

Figure 79: GlaxoSmithKline plc Financial Performance

Figure 80: PerkinElmer Inc. Financial Performance

Figure 81: BioMarin Pharmaceutical Inc. Financial Performance

Figure 82: Sarepta Therapeutics Inc. Financial Performance

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

Global Vutrisiran Market Trends: Regional Breakdowns and Strategic Insights

Vyndaqel Outlook 2034: Key Drivers, Trends, and Market Frontiers

Functional Dyspepsia DrugMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Duchenne Muscular Dystrophy Global Market Report 2025 – By Therapy (Mutation Suppression, Exon Skipping Approach), By Therapeutic Class (Molecular Based Therapies, Steroid Therapy), By Route of Administration (Oral, Pare...

Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2025 – By Type (Small Molecules, Biologics), By Distribution Channel (Offline, Online), By Application (Hospitals, Clinics, Home Care) – Impact of Tarif...

Muscle Wasting Disorders Global Market Report 2025 – By Treatment Type (Medications, Physical Therapy, Nutritional Therapy, Surgery, Gene Therapy, Other Treatment Types), By Disorder Type (Muscular Dystrophy, Amyotrophic...

Muscle Tension Dysphonia Treatment Global Market Report 2025 – By Treatment Type (Drugs, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Proton-Pump Inhibitors, Analgesics, Antacids, Voice Therapy, Behavioral Counseling),...

Muscle Spasticity Global Market Report 2025 – By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Other Drugs), By Route Of Administration (Oral, Intramuscular, Other Routes), By Distribution Channel (H...

Vitamin D Therapy Global Market Report 2025 – By Administration( Oral, Parenteral), By Purchasing( OTC Drugs, Prescription Drugs), By Age Group( Children, Adults, Senior Adults), By Application( Osteoporosis, Rickets, Sk...

Muscle Pain Treatment Global Market Report 2025 – By Pharmacological Treatment (Analgesics, Muscle Relaxants, Topical Analgesics, Other Pharmacological Treatments), By Non-Pharmacological Treatment (Physical Therapy, Mas...

Frequently Asked Questions

What is the definition of the Duchenne Muscular Dystrophy market?

How will the Duchenne Muscular Dystrophy market drivers and restraints affect the market dynamics? What forces will shape the Duchenne Muscular Dystrophy industry going forward?

The market major growth driver - Rising Prevalence Of Chronic Diseases Fuels Growth In The Duchenne Muscular Dystrophy Market. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Duchenne Muscular Dystrophy market?

The duchenne muscular dystrophy market size has grown strongly in recent years. It will grow from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to genetic understanding and diagnostic advances, clinical trial progress, patient advocacy and awareness, orphan drug designation and incentives, collaborative research initiatives. The duchenne muscular dystrophy market size is expected to see strong growth in the next few years. It will grow to " $1.72 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to emerging gene therapies, precision medicine approaches, expanded access to therapies, long-term follow-up studies, regulatory advancements. Major trends in the forecast period include integration of digital health technologies, technological advancements in therapeutics, gene therapies and genetic medicines, regulatory support for orphan drugs, precision medicine approaches. For further insights on this market, request a sample here

How is the Duchenne Muscular Dystrophy market segmented?

The duchenne muscular dystrophy market covered in this report is segmented –
1) By Therapy: Mutation Suppression, Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments:
1) By Mutation Suppression: Antisense Oligonucleotides (ASOs), Small Molecules, Gene Therapy
2) By Exon Skipping Approach: Exon-Skipping Therapies, Combination Therapies, Clinical Trials And Investigational Drugs For further insights on this market, request a sample here

Which region has the largest share of the Duchenne Muscular Dystrophy market? What are the other regions covered in the report?

North America was the largest region in the Duchenne muscular dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Duchenne Muscular Dystrophy market?

What are the key trends in the Duchenne Muscular Dystrophy market?

Major trends in this market include Technological Advancements In Clinical Trial Simulator Boost Duchenne Muscular Dystrophy Market. For further insights on this market, request a sample here.